GlassScriptPhysician profile
Pushpinder Uppal
NPI 1679077903
$3,181.85
in general payments reported to CMS, 2019-2025
15 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what 76% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $340 · 2024: $1,106 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,181.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,645.93 | 2023-2025 | Proclaim, Octrode, Eterna |
| Boston Scientific Corporation | $538.58 | 2023-2025 | Intracept, Wavewriter Alpha Prime 16, Na |
| Bioventus LLC | $226.94 | 2025 | |
| Biotronik Nro, INC. | $188.11 | 2024-2025 | Prospera |
| Nalu Medical, INC. | $144.82 | 2025 | Nalu Neurostimulation System |
| Stryker Corporation | $111.12 | 2025 | Blueprint Patient Specific Instrumentation |
| Medtronic, INC. | $85.48 | 2025 | Inceptiv, Intellis Adaptivestim |
| Lenoss Medical INC | $59.63 | 2024 | Access & Cavity Creation Kit |
| Avanos Medical | $42.24 | 2024 | Generator |
| Fidia Pharma USA INC. | $27.93 | 2024 | Hymovis |
| Saluda Medical Americas, INC. | $26.78 | 2024 | Evoke |
| Pacira Pharmaceuticals Incorporated | $25.96 | 2023 | Iovera |
| Painteq LLC | $22.51 | 2023 | Painteq |
| Mml US, INC. | $19.40 | 2025 | Reactiv8 |
| Nevro Corp. | $16.42 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pushpinder Uppal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.